16 May 2020

Lancet publishes results from a randomized, placebo-controlled, double- blinded trial of remdesivir (in combination with other medicines, including LPV/r, interferons, and corticosteroids) in people hospitalized with severe COVID-19. No significant differences in adverse events, viral clearance, time to recovery or mortality rates were reported, although the study was unable to reach full enrollment due to Wuhan’s waning epidemic. Source

Return to the timeline